Secureworks to Report Fourth Quarter and Full Year Fiscal 2024 Financial Results on March 14, 2024
Secureworks to Report Fourth Quarter and Full Year Fiscal 2024 Financial Results on March 14, 2024
PR Newswire
ATLANTA, Feb. 22, 2024
ATLANTA, Feb. 22, 2024 /PRNewswire/ -- Secureworks (NASDAQ: SCWX) today announced that it plans to release its fourth quarter and full year fiscal 2024 financial results on Thursday, March 14, 2024, before the open of regular U.S. stock market trading hours.
Secureworks® will host a conference call that day to review the results at 8:00 a.m. ET. A live audio webcast of the conference call will be accessible on the company's website at https://investors.secureworks.com. The webcast will be archived at the same location.
About Secureworks
Secureworks (NASDAQ: SCWX) is a global cybersecurity leader that secures human progress with Secureworks® Taegis™, a SaaS-based, open XDR platform built on 20+ years of real-world detection data, security operations expertise, and threat intelligence and research. Taegis is embedded in the security operations of over 4,000 organizations around the world who use its advanced, AI-driven capabilities to detect advanced threats, streamline and collaborate on investigations, and automate the right actions.
Connect with Secureworks via X, LinkedIn and Facebook
View original content to download multimedia:https://www.prnewswire.com/news-releases/secureworks-to-report-fourth-quarter-and-full-year-fiscal-2024-financial-results-on-march-14-2024-302069041.html
SOURCE Secureworks, Inc.
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth